Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Erratum: The antiepileptic drug levetiracetam improves auditory gating in DBA/2 mice

Subjects

The Original Article was published on 01 July 2015

Correction to: npj Schizophrenia 1, 15002 (2015). doi: 10.1038/npjschz.2015.2

We are submitting an erratum for our published article ‘The antiepileptic drug levetiracetam improves auditory gating in DBA/2 mice'. In the article abstract, the phrase ‘Low-dose LEV may improve P20-N40 gating in the DBA/2 mouse model of schizophrenia’ appears twice. The abstract should read:

‘…No other doses significantly affected gating. Low doses of LEV may improve P20-N40 gating in the DBA/2 mouse model of schizophrenia and warrant further investigation in the illness.’

Authors

Additional information

The online version of the original article can be found at 10.1038/npjschz.2015.25

Rights and permissions

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Smucny, J., Stevens, K. & Tregellas, J. Erratum: The antiepileptic drug levetiracetam improves auditory gating in DBA/2 mice. npj Schizophr 1, 15053 (2015). https://doi.org/10.1038/npjschz.2015.53

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing